OBJECTIVE: Fibroblast growth factor 9 (FGF-9) is a relatively new member of the FGF family isolated from the conditioned medium of a human glioblastoma cell line as a secreting type factor that exhibits a growth-stimulating effect on primary glial cells. To elucidate the roles of FGF-9 in human brain tumors, the expression and biological activities of FGF-9 were studied using culture cells and surgically obtained tumor specimens. METHODS: Measurement of FGF-9 and basic FGF in conditioned media of cell cultures was performed by using a sandwich enzyme immunoassay. The mitogenic effect of FGF-9 was evaluated by cell growth studies. FGF-9 expression in vivo was demonstrated by immunohistochemistry. RESULTS: One of 4 glioma cell lines and 4 of 16 human meningiomas examined actually secreted detectable amounts of FGF-9 proteins. In comparison, basic FGF production was detected from 3 of 4 glioma cell lines and 11 of 16 human meningiomas. Similarly to basic FGF, recombinant human FGF-9 significantly stimulated the in vitro cell proliferation in three of four glioma cell lines investigated in a dose-dependent manner. A time course growth study using U87 MG cells revealed an accelerated growth stimulation by FGF-9 after Day 4. The growth stimulatory activity was also shown in three of four human meningiomas studied. Moderate to strong immunoreactivity for FGF-9 was observed in 40 (82%) of 49 human brain tumors examined irrespective of origin, tumor type, grade of malignancy, or whether initial or recurrent. In contrast, strong immunostaining was localized in neurons in the normal human cerebral cortex. CONCLUSION: The present findings suggest that FGF-9 may be involved in the biology of human brain tumors with a possible importance in tumor cell growth. Whether the growth factor is more generally involved in oncogenesis of human tumors awaits further investigation.
OBJECTIVE:Fibroblast growth factor 9 (FGF-9) is a relatively new member of the FGF family isolated from the conditioned medium of a humanglioblastoma cell line as a secreting type factor that exhibits a growth-stimulating effect on primary glial cells. To elucidate the roles of FGF-9 in humanbrain tumors, the expression and biological activities of FGF-9 were studied using culture cells and surgically obtained tumor specimens. METHODS: Measurement of FGF-9 and basic FGF in conditioned media of cell cultures was performed by using a sandwich enzyme immunoassay. The mitogenic effect of FGF-9 was evaluated by cell growth studies. FGF-9 expression in vivo was demonstrated by immunohistochemistry. RESULTS: One of 4 glioma cell lines and 4 of 16 humanmeningiomas examined actually secreted detectable amounts of FGF-9 proteins. In comparison, basic FGF production was detected from 3 of 4 glioma cell lines and 11 of 16 humanmeningiomas. Similarly to basic FGF, recombinant humanFGF-9 significantly stimulated the in vitro cell proliferation in three of four glioma cell lines investigated in a dose-dependent manner. A time course growth study using U87 MG cells revealed an accelerated growth stimulation by FGF-9 after Day 4. The growth stimulatory activity was also shown in three of four humanmeningiomas studied. Moderate to strong immunoreactivity for FGF-9 was observed in 40 (82%) of 49 humanbrain tumors examined irrespective of origin, tumor type, grade of malignancy, or whether initial or recurrent. In contrast, strong immunostaining was localized in neurons in the normal human cerebral cortex. CONCLUSION: The present findings suggest that FGF-9 may be involved in the biology of humanbrain tumors with a possible importance in tumor cell growth. Whether the growth factor is more generally involved in oncogenesis of humantumors awaits further investigation.
Authors: Charles Vragniau; Jens-Martin Hübner; Peter Beidler; Sucheol Gil; Kamola Saydaminova; Zhuo-Zhuang Lu; Roma Yumul; Hongjie Wang; Maximilian Richter; Pavel Sova; Charles Drescher; Pascal Fender; André Lieber Journal: J Virol Date: 2017-02-28 Impact factor: 5.103
Authors: S Allerstorfer; G Sonvilla; H Fischer; S Spiegl-Kreinecker; C Gauglhofer; U Setinek; T Czech; C Marosi; J Buchroithner; J Pichler; R Silye; T Mohr; K Holzmann; B Grasl-Kraupp; B Marian; M Grusch; J Fischer; M Micksche; W Berger Journal: Oncogene Date: 2008-03-24 Impact factor: 9.867
Authors: Heiko Fensterer; Bernhard Radlwimmer; Jörn Sträter; Malte Buchholz; Daniela E Aust; Catherine Julié; François Radvanyi; Bernard Nordlinger; Claudio Belluco; Eric Van Cutsem; Claus-Henning Köhne; Hans A Kestler; Carsten Schwaenen; Michelle Nessling; Manfred P Lutz; Peter Lichter; Thomas M Gress Journal: BMC Cancer Date: 2007-04-02 Impact factor: 4.430
Authors: Adriana Olar; Lindsey D Goodman; Khalida M Wani; Nicholas S Boehling; Devi S Sharma; Reema R Mody; Joy Gumin; Elizabeth B Claus; Frederick F Lang; Timothy F Cloughesy; Albert Lai; Kenneth D Aldape; Franco DeMonte; Erik P Sulman Journal: Oncotarget Date: 2018-02-15